This was further demonstrated in the results of the ELIXA trial evaluating the cardiovascular effects of lixisenatide, a short‐acting GLP‐1 RA, in patients with type 2 diabetes and a recent episode of acute coronary syndrome. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.